Assertio Therapeutics (ASRT) Misses Q1 EPS by 9c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.49 million versus the consensus estimate of $27.52 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Rocket Lab launches U.S. Space Force mission in record 16 hours
• South Korea's KOSPI Plunges 8%, Triggering Circuit Breaker